Gleason IP
< Back to NewsApril 22, 2024
Recent Changes to the Federal Rules of Evidence Governing the Admissibility of Expert Testimony Effective December 1, 2023, the Federal Rules of Evidence relating to the admissibility of expert testimony were amended. The Federal Advisory Committee on Evidence Rules (the “Committee”) indicated that Rule 702 (Testimony by Expert Witness) was amended in order to clarify... Read More
January 19, 2024
Federal Circuit Affirms Use of Skinny Label for Vortioxetine In December 2023, the United States Court of Appeals for the Federal Circuit affirmed a district court’s opinion regarding noninfringement of two patents related to specific uses of the antidepressant drug Trintellix® (vortioxetine). This opinion reaffirmed the use of the “section viii” statement, allowing companies... Read More
October 2, 2023
Delaware Chief Judge Connolly Credits Ivan Hofmann’s Commercial Success Testimony in a Pharmaceutical Patent Case Gleason IP was retained by multiple defendants in a patent infringement matter related to Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc.’s Lonsurf® (trifluridine and tipiracil) tablets. Lonsurf® tablets are a prescription medicine for stomach cancer (sometimes referred to... Read More
July 20, 2023
Federal Circuit Affirms the Use of Blocking Patents in a Commercial Success Inquiry In the patent litigation between UCB and Actavis related to the reformulated Neupro® patch, the Federal Circuit affirmed the District Court’s decision regarding Ivan Hofmann’s testimony related to blocking patents that dissuaded competitors from developing a rotigotine patch that practiced the claimed... Read More
Gleason IP Testimony Supports Client’s Successful Case
August 3, 2020
Gleason IP provided expert testimony on behalf of Teva Pharmaceuticals to establish that the asserted patent claims allegedly covering Adapt Pharma’s opioid overdose drug were invalid due to obviousness, and that the marketplace performance of Narcan® was attributable to features already known in the prior art, among other extrinsic factors unrelated to the Patents-in-Suit. Engagement In... Read More
Remote Depositions in Response to COVID-19
August 3, 2020
The COVID-19 pandemic and related stay-at-home directives have led to an increase in remote depositions. Historically, attorneys have been reluctant to conduct remote depositions, but there can be certain advantages to be gained from their adoption. On several occasions, Gleason Managing Directors have been deposed virtually and are providing insight for consideration to aid in... Read More
Pricing in the Pharmaceutical Industry
August 3, 2020
Drug pricing in the United States has been a political hot topic in recent years. On July 24, 2020, President Trump signed four executive orders on lowering drug prices. This multifaceted issue has numerous stakeholders with far reaching financial impacts. The backdrop of the current global pandemic creates additional complications for pharmaceutical companies seeking to... Read More
August 3, 2020
Recently the practice of establishing so called patent-thickets for biologic products has been questioned as a potentially abusive way of preventing biosimilar competition. In June 2020, the Honorable Judge Manish S. Shah in the United States District Court for the Northern District of Illinois Eastern Division issued a Memorandum Opinion and Order dismissing a class... Read More
Spring Continuing Legal Education Series
April 11, 2019
Fairmont Hotel | 501 Market Street, Pittsburgh, PA 15222 April 10, 12:00-1:00 pm | May 7, 7:30-8:30 am | June 5, 7:30-8:30 am Gleason is pleased to present a series of continuing legal education sessions at the Fairmont Hotel in downtown Pittsburgh. Each of these sessions will cover different topics, which are detailed below. Please feel... Read More
Navigating Patent Litigation Changes: Update on the America Invents Act
January 1, 2017
In Issue 3 of IP Insights, we discussed the Inter Partes Review (IPR) process at the United States Patent and Trademark Office (USPTO) since the Leahy-Smith America Invents Act (AIA) was signed into law. The AIA was approved as part of an effort to improve the quality of the patents issued by the USPTO, to... Read More
Increased Attention on Pharmaceutical Prices
January 1, 2017
As healthcare costs continue to rise, more and more people have entered the debate over escalating drug prices. One situation that has captured the attention of many involves the drug Daraprim®. Daraprim® (pyrimethamine) is used to treat toxoplasmosis in patients with weak immune systems, such as HIV patients.1 Although Daraprim® has been around for over... Read More
Gleason IP Helps Clients Win Patent Infringement Case
January 1, 2017
Engagement In a pharmaceutical patent infringement matter, Ivan Hofmann and the team at Gleason IP analyzed various issues and provided expert opinions and testimony concerning objective indicia of nonobviousness related to a patent that allegedly covered a lyophilized formulation of the injectable cancer drug bortezomib (marketed as Velcade®). Specifically, Gleason IP analyzed commercial success as... Read More